Incorporated in September 1995, Encube Ethicals Limited is a global pharmaceutical formulations company specializing in topical and transdermal dosage forms, serving 50 countries, including regulated markets such as the …
Incorporated in September 1995, Encube Ethicals Limited is a global pharmaceutical formulations company specializing in topical and transdermal dosage forms, serving 50 countries, including regulated markets such as the United States, the UK, Europe, and India. The company operates through three integrated business verticals: Global Generics, Global CDMO (Contract Development and Manufacturing Organization), and India Branded Formulations, providing end-to-end capabilities across research & development, formulation development, manufacturing, regulatory compliance, and commercialization. It is one of the fastest-growing players in the US topical generics market and has a strong presence in regulated international markets.Encube operates large-scale regulatory-approved manufacturing facilities supported by advanced R&D infrastructure, a robust innovation pipeline, and long-standing relationships with leading global pharmaceutical companies. The company also markets branded topical products in India through an established distribution network.Encube focuses on innovation, quality, regulatory compliance, and customer-centric product development.As of March 31, 2026, the company had 1,695 permanent employees and 982 factory workers across production, R&D, quality, supply chain, finance, IT, and commercial functions.StrengthsLarge-scale regulatory-approved manufacturing with a strong compliance record.Strong R&D capabilities driving innovation and product pipeline.Integrated business model across Global Generics, CDMO, and India Branded Formulations.Fast-growing presence in the US topical generics market and strong global customer relationships.Experienced leadership team with a proven track record of business growth and transformation.
📍 803, B Wing HDIL Kaledonia, Sahar Road Andheri East Mumbai, Maharashtra, 400069
📞 22 62288000
✉️ compliance.cs@encubeethicals.com
Encube Ethicals Ltd IPO About the Company
Incorporated in September 1995, Encube Ethicals Limited is a global pharmaceutical formulations company specializing in topical and transdermal dosage forms, serving 50 countries, including regulated markets such as the United States, the UK, Europe, and India. The company operates through three integrated business verticals: Global Generics, Global CDMO (Contract Development and Manufacturing Organization), and India Branded Formulations, providing end-to-end capabilities across research & development, formulation development, manufacturing, regulatory compliance, and commercialization. It is one of the fastest-growing players in the US topical generics market and has a strong presence in regulated international markets.Encube operates large-scale regulatory-approved manufacturing facilities supported by advanced R&D infrastructure, a robust innovation pipeline, and long-standing relationships with leading global pharmaceutical companies. The company also markets branded topical products in India through an established distribution network.Encube focuses on innovation, quality, regulatory compliance, and customer-centric product development.As of March 31, 2026, the company had 1,695 permanent employees and 982 factory workers across production, R&D, quality, supply chain, finance, IT, and commercial functions.StrengthsLarge-scale regulatory-approved manufacturing with a strong compliance record.Strong R&D capabilities driving innovation and product pipeline.Integrated business model across Global Generics, CDMO, and India Branded Formulations.Fast-growing presence in the US topical generics market and strong global customer relationships.Experienced leadership team with a proven track record of business growth and transformation.
Encube Ethicals Ltd IPO Analysis
Pros
ROE of 25.65% indicates good return on equity.
ROCE of 32.30% shows efficient capital usage.
PAT margin of 23.62%.
Cons
Detailed analysis available after listing.
Pros and cons are machine generated. Please exercise caution and do your own analysis.
Encube Ethicals Ltd IPO Subscription Status
Consolidated figures
Metric
QIB
NII (HNI)
Retail
Total
Subscription
—
—
—
—
Shares
Not more than 50% of the Offer
Not less than 15% of the Offer
Not less than 35% of the Offer
—
Bids
—
—
—
—
▼ Category-wise Detailed Breakdown
Category
Subscription
Offered
Bid Shares
Amt (₹ Cr)
QIB
-
Not more than 50% of the Offer
—
—
NII (HNI)
-
Not less than 15% of the Offer
—
—
Retail
-
Not less than 35% of the Offer
—
—
Market Maker
1.00×
—
—
—
Total
-
100
—
—
Applications: -
Encube Ethicals Ltd IPO Profit & Loss
Figures in ₹ Crores / Amount in ₹ Crore
Metric
31 Mar 2026
31 Mar 2025
31 Mar 2024
Revenue
1,911.80
1,369.00
1,098.20
EBITDA
663.30
452.10
297.60
Profit After Tax
436.70
249.60
156.10
Net Worth
1,953.60
1,512.80
1,258.40
Total Assets
2,792.10
2,300.10
1,871.80
Reserves
1,915.20
1,495.20
1,243.40
Borrowings
221.70
230.50
228.10
Sales Growth
3 Years:
-42.6%
Latest:
1,098.20 Cr
Profit Growth
3 Years:
-64.3%
Latest PAT:
156.10 Cr
Return on Equity
ROE:
25.65%
ROCE:
32.30%
Encube Ethicals Ltd IPO Key Financial Ratios
Profitability
ROE25.65%
ROCE32.30%
RONW25.21%
PAT Margin23.62%
EBITDA Margin35.88%
Valuation
Pre EPS14.37
Post EPS14.37
Leverage & Growth
Debt / Equity0.13×
Sales Growth (3yr)-42.6%
Profit Growth (3yr)-64.3%
Latest Revenue1,098.20 Cr
Latest PAT156.10 Cr
Encube Ethicals Ltd IPO Schedule & Important Dates
IPO Open
TBA
Upcoming
IPO Close
TBA
Upcoming
Encube Ethicals Ltd IPO Lot Size & Investment Details